Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802

LG Chem42 enrolled

Overview

The purpose of this study is to evaluate the drug-drug interaction between LGEV1801 and LGEV1802 in healthy male volunteers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy Male Volunteers

Interventions

ValsartanDRUG

Valsartan P.O

Ezetimibe/RosuvastatinDRUG

Ezetimibe/Rosuvastatin P.O

Eligibility

Sex: MALEMin age: 19 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male * Age between 19 and 50 * Subjects with BMI of 18\~27 kg/m2 with a weight of 55kg or more * Subjects with SBP of 90\~150 mmHg and DBP of 60\~150 mmHg * Signed informed consent Exclusion Criteria: * Presence of medical history or a concurrent disease * Has a history of hypersensitivity to IP ingredients

Locations (1)

LG chem

Seoul, Gangseo-Gu, South Korea

Outcomes

Primary Outcomes

AUCT,ss

Time frame: Day 1~Day 8

Cmax,ss

Time frame: Day 1~ Day 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.